SWOG clinical trial number
CTSU/E2902

A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission after Primary Induction Failure or Patients Over Age 60 in First Remission

Closed
Phase
Abbreviated Title
Phase III AML in Second or Subsequent Remission or in Remission after Primary Induction Failure
Activated
10/01/2004
Closed
06/01/2007
Participants
CTSU

Research committees

Leukemia

Treatment

R115777

Eligibility Criteria Expand/Collapse

The Southwest Oncology Group participated in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU web site (http://www.ctsu.org/) for information.

Publication Information Expand/Collapse

2021

Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial

S Luger;V Wang;J Rowe;M Litzow;E Paietta;R Kettering;H Lazarus;W Rybka;M Craig;J Karp;B Cooper;A Makary;L Kaminer;F Appelbaum;R Larson;M Tallman Leukemia Research Dec;111:106736

PMid: PMID34773794 | PMC number: PMC8643322

2015

Tipifarnib as maintenance therapy In acute myeloid leukemia (AML) improves survival in women with high risk disease. Results of the phase III intergroup trial E2902

S Luger;X Yao;E Paietta;R Ketterling;W Rybka;M Litzow;JM Rowe;R Larson;F Appelbaum;M Tallman Blood 126(23):1308; American Society of Hematology Annual Meeting (Dec 5-8, 2015, Orlando, FL), poster;

Other Clinical Trials

SWOG Clinical Trial Number
S2507

A Phase II Randomized Study of Blinatumomab with or without Revumenib for Patients with KMT2A Translocation B-Cell Acute Lymphoblastic Leukemia (ALL)/ Acute Leukemia With Ambiguous Lineage (ALAL) with Persistent Measurable Residual Disease (MRD)
Research Committee(s)
Leukemia
Other
Activated
09/22/2026
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2504

A Randomized Phase III Study of PIRtobrutinib plus R-CHOP vs. R-CHOP for Patients with Previously UntreateD RIchter TrAnsforMation (RT) (pirAMID)
Research Committee(s)
Leukemia
Lymphoma
Activated
06/01/2026
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
CTSU/A042302

Phase III Evaluation of Fixed Duration Zanubrutinib Plus Sonrotoclax-Based Therapy Compared to Continuous Zanubrutinib in Previously Untreated Older Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Research Committee(s)
Leukemia
Activated
03/06/2026
Open
Phase